Gene editing for heart disease: Verve kicks off landmark base editing trial
Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base editing.
Now officially in a Phase Ib clinical trial in New Zealand, VERVE-101 is a single base editor designed to permanently turn off the PCSK9 gene in patients with heterozygous familial hypercholesterolemia, who have dangerously high cholesterol levels.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.